1. Home
  2. CAN vs IVVD Comparison

CAN vs IVVD Comparison

Compare CAN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.42

Market Cap

427.9M

Sector

Technology

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.14

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
IVVD
Founded
2013
2020
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
427.9M
437.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CAN
IVVD
Price
$0.42
$1.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$3.21
$8.75
AVG Volume (30 Days)
9.8M
2.6M
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$61.57
Revenue Next Year
$63.64
$41.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$0.38
$0.49
52 Week High
$2.22
$3.07

Technical Indicators

Market Signals
Indicator
CAN
IVVD
Relative Strength Index (RSI) 38.25 38.14
Support Level $0.39 $1.04
Resistance Level $0.56 $1.14
Average True Range (ATR) 0.03 0.10
MACD -0.01 -0.01
Stochastic Oscillator 20.57 20.72

Price Performance

Historical Comparison
CAN
IVVD

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: